A highly anticipated trial testing exenatide, a GLP-1 drug similar to Ozempic, found no evidence that it slows the progression of Parkinson’s disease. Researchers had hoped these drugs, which have shown promise for weight loss and diabetes, might also protect neurons and alter the course of neurodegeneration. But after 96 weeks, the study showed no significant impact on symptoms, brain scans, or disease progression. While disappointing, this finding highlights the challenges of translating lab-based discoveries into real-world treatments. As Dr. Okun noted, rigorous trials like these are critical to refining our understanding of Parkinson’s and guiding future research. Read more: nytimes.com/2025/02/04/health/parkinsons-disease-exenatide-byetta.html# #ParkinsonsResearch #FixelInstitute #Neurodegeneration